Moreover, gefitinib treatment in high-fat diet Mig-6d/d mice showed decreases in fasting insulin concentration and insulin resistance, suggesting gefitinib may improve metabolic syndrome in those with dysregulated EGFR and/or its signaling pathway. This evidence concerns the gene EGFR and metabolic syndrome.